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Abstract 
In many skeletal diseases, including osteoporosis and disuse osteopenia, defective osteoblast 
differentiation is associated with increased marrow adipogenesis. The relative activity of two 
transcription factors, RUNX2 and PPAR!, controls whether a mesenchymal cell will differentiate 
into an osteoblast or adipocyte. Herein we show that the ERK/MAP kinase pathway, an 
important mediator of mechanical and hormonal signals in bone, stimulates osteoblastogenesis 
and inhibits adipogenesis via phosphorylation of RUNX2 and PPAR!. Induction of 
osteoblastogenesis in ST2 mesenchymal cells was associated with increased MAPK activity and 
RUNX2 phosphorylation. Under these conditions PPAR! phosphorylation also increased, but 
adipogenesis was inhibited. In contrast, during adipogenesis MAPK activity and phosphorylation 
of both transcription factors was reduced. RUNX2 phosphorylation and transcriptional activity 
were directly stimulated by MAPK, a response requiring phosphorylation at S301 and S319. 
MAPK also inhibited PPAR!-dependent transcription via S112 phosphorylation. Stimulation of 
MAPK increased osteoblastogenesis and inhibited adipogenesis, while dominant-negative 
suppression of activity had the opposite effect. In rescue experiments using Runx2-/- mouse 
embryo fibroblasts (MEFs), wild type or, to a greater extent, phosphomimetic mutant RUNX2 
(S301E,S319E) stimulated osteoblastogenesis while suppressing adipogenesis. In contrast, a 
phosphorylation-deficient RUNX2 mutant (S301A,S319A) had reduced activity. Conversely, 
wild type or, to a greater extent, phosphorylation-resistant S112A mutant PPAR! strongly 
stimulated adipogenesis and inhibited osteoblastogenesis in Pparg -/- MEFs, while S112E mutant 
PPAR! was less active. Competition between RUNX2 and PPAR! was also observed at the 
transcriptional level. Together, these studies highlight the importance of MAP kinase signaling 
and RUNX2/PPAR! phosphorylation in the control of osteoblast and adipocyte lineages.  
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Introduction 
 The therapeutic control of bone formation requires an understanding of signals controlling 
cell fate and differentiation. The ERK/MAP kinase (MAPK) pathway controls the response of 
osteoprogenitors and mesenchymal stem cells to changes in extracellular matrix (ECM) 
composition and stiffness, mechanical loading, hormone, growth factor and morphogen 
stimulation (Kapur et al., 2005; Khatiwala et al., 2009; Li et al., 2012; Xiao et al., 2002a; Xiao et 
al., 2002b; Xiao et al., 1998; You et al., 2001). Here we explore the possibility that this pathway 
is an important inducer of mesenchymal cell differentiation toward osteoblasts and away from 
adipocytes. 
 Osteoporosis and disuse osteopenia are frequently associated with decreased osteoblast 
activity and increased marrow fat (Justesen et al., 2001; Meunier et al., 1973; Minaire et al., 
1984). Furthermore, the differentiation of marrow stem cells to osteoblasts or adipocytes is 
reciprocally controlled; conditions that favor osteoblast differentiation generally inhibit 
adipogenesis, while those favoring adipocyte formation inhibit osteoblastogenesis (Jaiswal et al., 
2000; Kang et al., 2007; Marie and Kaabeche, 2006; Moerman et al., 2004; Nuttall et al., 2014). 
Although the basis for this regulation is not understood, some studies suggest involvement of the 
MAPK pathway. For example, chemical inhibition of MAPK activity in marrow stromal cells 
(MSCs) increases adipocyte formation, while MAPK activation induces osteoblastogenesis 
(Jaiswal et al., 2000). Moreover, growth of MSCs on stiff versus soft substrates increases MAPK 
downstream of RhoA and ROCK, thereby stimulating osteoblast formation and inhibiting 
adipogenesis (Engler et al., 2006; Khatiwala et al., 2009; McBeath et al., 2004). 
 Two key regulators of mesenchymal cell differentiation to osteoblasts or adipocytes are the 
transcription factors RUNX2 and PPAR!, which are required for bone and fat formation, 
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respectively (Otto et al., 1997; Rosen et al., 1999). The relative activity of RUNX2 versus 
PPAR! determines whether a mesenchymal progenitor undergoes osteoblastogenesis or 
adipogenesis. Indeed, cells from Runx2-null mice, which cannot form bone, spontaneously 
differentiate into adipocytes (Enomoto et al., 2004) while PPAR!-null mouse embryo fibroblasts 
(MEFs) fail to differentiate into adipocytes, but spontaneously form osteoblasts(Akune et al., 2004). 
Furthermore, PPAR! haploinsufficiency increases bone mass while transgenic overexpression of 
PPAR! in osteoblasts reduces bone (Akune et al., 2004; Cho et al., 2011).  
 Significantly, both Runx2 and PPAR! are regulated by MAPK-dependent phosphorylation. 
ERK phosphorylates RUNX2 on several serine residues including S301 and S319, which are 
both required for RUNX2-dependent transcription (Ge et al., 2009). These phosphorylation 
events are necessary for the response of osteoblasts to several important stimuli, including ECM 
synthesis, mechanical loading, FGF2 and BMP treatment (Ge et al., 2009; Ge et al., 2012; 
Greenblatt et al., 2010; Li et al., 2012). Similarly, PPAR! undergoes ERK-dependent 
phosphorylation at S112, which inhibits its transcriptional activity and suppresses adipocyte 
differentiation (Hu et al., 1996; van Beekum et al., 2009).  
 Here we directly examine the role of MAPK-dependent phosphorylation on osteoblast and 
adipocyte differentiation of mesenchymal cells. We find that elevated MAPK activity is 
associated with osteoblast differentiation while reduced activity is associated with adipogenesis. 
Furthermore, phosphorylation of RUNX2 and PPAR! is required both to stimulate osteoblast 
differentiation and suppress adipogenesis. 
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Methods and Methods 
DNA constructs and viral expression vectors. The 6OSE2-luc reporter, pCMV wild type 
Runx2 (RUNX2-WT), S301,319A Runx2 (RUNX2-SA) and S301,319E Runx2 (RUNX2-SE 
expression vectors were previously described (Ge et al., 2009) as were ARE-luc, RXR, wild type 
PPAR! (PPAR!-WT), S112A PPAR! (PPAR!-SA), S112E PPAR! (PPAR!-SE) (Camp and 
Tafuri, 1997; Perez et al., 1993), constitutively active MEK1 (Meksp) and dominant negative 
MEK1 (Mekdn) expression vectors (Zheng and Guan, 1993). Adenovirus expressing Meksp and 
Mekdn were generated by subcloning the cDNA of Meksp and Mekdn into Adloxp shuttle vector 
and generating adenovirus using Cre-Lox recombination (Hardy et al., 1997). Retrovirus 
expression vectors for wild type and mutant RUNX2 and PPAR! were developed by subcloning 
appropriate cDNAs into the retrovirus vector, pLXSN (Clontech). Adenovirus and retrovirus 
were produced in the University of Michigan Vector. 
 
Cells Cultures. COS7 cells were obtained from the American Type Culture Collection. ST2 
cells (Ogawa et al., 1988) were obtained from Dr. Kurt Hankenson (Michigan State University) 
and PPAR! knockout MEFs were obtained from Evan Rosen (Harvard University) (Rosen et al., 
2002). Runx2-knockout MEFs were generated from E12.5 Runx2-knockout mice as previously 
described (Ge et al., 2009). Osteoblast differentiation was induced in ST2 and MEF cells by 
growth in "-MEM/10%FBS containing 50"g/ml ascorbic acid, 10 mM #-glycerophosphate and 
3 "M Chrion 99021 (Cayman Chemicals). For adipogenesis, cells were grown for 2 days in 
alpha medium containing 10% FBS, insulin (5 "g/ml), dexamethasone (1 "M), IBMX (500 "M) 
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and troglitazone (5 "M), followed by growth in medium containing troglitazone (5 "M) only for 
up to 9 days (Cawthorn et al., 2012). 
 
Transfection and transduction. COS7 cells were transfected with the indicated plasmids using 
Lipofectamine (Invitrogen) and assayed for luciferase activity as previously described (Ge et al., 
2009). ST2 cells were transduced using adenovirus expressing LacZ, Meksp or Mekdn (200 
pfu/cell). After overnight virus treatment, cells were transferred to osteoblast or adipocyte 
induction medium. For development of stable cell lines, MEFs from Runx2 -/- or Ppar! -/- 
embryos were transduced using retroviral vectors expressing wild type or mutant Runx2 or 
PPAR!, and then selected by growth in 200 µg/ml Geneticin for 4 weeks. The resulting stable 
cell pools were then grown in osteogenic or adipogenic conditions for analysis. 
 
Western blot and RNA Analysis, mineral and lipid staining. Sources for antibodies were as 
follows: total Runx2 antibody, MBL; PPAR! phospho-S112-specific antibody and total PPAR! 
antibody, Millipore; phospho-ERK1/2 and total ERK1/2 antibody, Cell Signaling. Runx2 
phospho-S319 -specific antibody was previously described(Ge et al., 2012). Western blot 
analysis was performed using standard procedures. RNA was isolated using TRIzol reagent 
(Invitrogen). Reverse transcriptase reactions were conducted with 2 µg of total RNA, TaqMan 
reverse transcriptase reagents, and an oligo(dT) primer (Applied Biosystems). All mRNAs were 
measured by quantitative reverse transcription polymerase chain reactions using predeveloped 
Taqman probes and primers. Glyceradehyde-3-phosphate dehydrogenase mRNA used as an 
internal control(Ge et al., 2009). Visualization of mineralization and fat droplet accumulation 
was achieved using Alizarin Red and Oil Red O staining. Cell images were taken using a phase 
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contrast microscope (Nikon D300). 
 
Statistical analysis. All statistical analyses were performed using SPSS 16.0 Software. Unless 
indicated otherwise, each reported value is the mean ± S.D. of triplicate independent samples. 
Statistical significance was assessed using a one-way analysis of variance. 
 
Results 
Preferential association of elevated MAP kinase activity and transcription factor 
phosphorylation with osteoblast differentiation. When cultured in the appropriate inductive 
media, marrow stromal cells and mesenchymal cell lines such as murine ST2 cells can 
differentiate into either osteoblasts or adipocytes (Cawthorn et al., 2012). This is shown in Figure 
1, where ST2 cells were cultured for up to 2 weeks in growth, osteogenic or adipogenic medium 
and assayed for mineral formation and fat droplet accumulation (Fig. 1A), or osteoblast and 
adipocyte marker mRNA expression (Fig. 1C-I).  Osteogenic medium increased mineralization 
and osteoblast marker mRNAs (Runx2, Bglap2 and Ibsp) while suppressing fat droplet 
accumulation and adipocyte markers (Pparg, Cebpa, Adipoq, Fabp4). In contrast, growth in 
adipogenic medium had the opposite effect, with increased fat accumulation and adipocyte 
marker expression and decreased osteoblastogenesis (Fig. 1A, C-I). Consistent with previous 
reports using osteoblast cultures (Ge et al., 2012), growth of ST2 cells in osteogenic conditions 
increased phosphorylation of ERK1/2 and RUNX2 (Fig. 1B).  Although ERK phosphorylates 
RUNX2 at several sites (Ge et al., 2009), the S319 phosphorylation measured in this experiment 
closely correlates with overall RUNX2 transcriptional activity and osteoblast differentiation (Ge 
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et al., 2012). Growth under osteogenic conditions also increased PPAR!-S112 phosphorylation, a 
modification known to decrease its transcriptional activity (Hu et al., 1996). In contrast, growth 
in adipogenic medium was associated with decreased MAPK activity and reduced 
phosphorylation of both RUNX2 and PPAR! (Fig. 1B). 
 
MAPK-dependent phosphorylation stimulates RUNX2 transcriptional activity while 
suppressing PPAR! . The transcriptional activities of both RUNX2 and PPAR! are directly 
regulated by MAPK-dependent phosphorylation, with mutational analysis identifying crucial 
roles for phosphorylation of S301 and S319 in RUNX2 (Ge et al., 2009) and for S112 in PPAR! 
(Hu et al., 1996). The importance of these phosphorylation sites in RUNX2 and PPAR! 
regulation is shown in Figure 2. COS7 cells were transfected with either RUNX2 (6OSE2-luc) or 
PPAR! reporter plasmids (ARE-luc) and the ability of MAP kinase to regulate RUNX2- or 
PPAR!-dependent transcriptional activity was measured. Wild type RUNX2 increased basal 
6OSE2-luc activity, a response that was stimulated nearly 3-fold by co-transfection with a 
constitutively active mutant of the MAPK intermediate, MEK1 (Panel A). In contrast, 
transfection with dominant-negative MEK1 reduced basal RUNX2 activity. A RUNX2-
S301A,S319A mutant (RUNX2-SA) was partially resistant to MAPK stimulation while a mutant 
containing phosphomimetic S301E,S319E mutations (RUNX2-SE) (Ge et al., 2009) had high 
basal transcriptional activity that was not further stimulated by MAPK activation. Consistent 
with these results, RUNX2 S319 phosphorylation was markedly stimulated with constitutively-
active MEK1 and suppressed with dominant-negative MEK1 (Panel B).  
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 MAPK regulation of PPAR! is shown in Figure 2C,D.  Expression of wild type PPAR! with 
the co-regulator RXR increased basal activity of the ARE-luc reporter and this was further 
stimulated with the agonist troglitazone (TZD). In contrast to results with RUNX2, constitutively 
active MEK strongly suppressed PPAR! transcriptional activity while dominant-negative MEK 
increased transcription relative to PPAR! alone. Mutation of PPAR! S112 to alanine also 
increased transcriptional activity and this stimulation was resistant to inhibition by constitutively 
active MEK. In contrast, the PPAR! S112E phosphomimetic mutant had reduced activity that 
was not affected by MAPK. Immunoblotting revealed increased PPAR! S112 phosphorylation 
with constitutively active MEK1 and reduced phosphorylation with dominant-negative MEK1 
(Panel D). Taken together, these results confirm that MAPK phosphorylates RUNX2 and 
PPAR!, resulting in increased RUNX2-dependent transcription and suppression of PPAR! 
activity.  
 
MAP kinase stimulates osteoblast differentiation while inhibiting adipogenesis. To more 
directly examine effects of MAP kinase on osteoblast and adipocyte differentiation, ST2 cells 
were transduced with adenoviral vectors encoding constitutively active (Meksp) or dominant-
negative MEK1 (Mekdn) and osteoblast or adipocyte differentiation was measured (Fig. 3). In 
cells grown in osteogenic medium, Meksp increased P-ERK and RUNX2 phosphorylation after 2 
or 8 days while Mekdn suppressed both of these responses without altering total Runx2 protein 
or mRNA levels (Fig. 3B,C). These changes were associated with increased mineralization and 
expression of osteoblast marker mRNAs in Meksp-transduced cells and suppression of these 
parameters with Mekdn (Fig. 3A-E). The opposite result was obtained in a parallel experiment 
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where ST2 cells were grown under adipogenic conditions (Fig. 3F-K). In this case, Meksp 
increased PPAR! S112 phosphorylation, but suppressed PPAR! mRNA and protein, lipid 
accumulation and adipocyte marker expression while Mekdn decreased PPAR! phosphorylation 
and increased PPAR! protein and mRNA, lipid droplet accumulation and adipogenesis markers. 
For both osteoblast and adipocyte differentiation, effects of Mekdn were greater than those for 
Meksp. Mekdn strongly inhibited mineralization and osteoblast marker mRNAs in cells grown in 
osteogenic medium while stimulating lipid droplet accumulation and adipocyte markers in 
adipogenic medium. This is likely explained by the relatively high basal levels of P-ERK, P-
RUNX2 and P-PPAR! in ST2 cells that were suppressed by Mekdn, but only modestly increased 
by Meksp (e.g. Fig. 3B,G). Results could not be explained by differences in cell density or 
proliferation, which were similar for all groups (not shown). 
 
Control of osteoblast and adipocyte differentiation requires specific phosphorylation sites 
on RUNX2 and PPAR! . To more directly assess the roles of RUNX2 and PPAR! 
phosphorylation sites in the reciprocal control of osteoblast versus adipocyte differentiation, we 
conducted rescue experiments where wild type or phosphorylation site mutant RUNX2 or 
PPAR! were stably expressed in MEFs from Runx2 -/- or Pparg -/- embryos, respectively.  
 Before conducting these studies, we first characterized Runx2 -/- and Pparg -/- MEFs (Suppl. 
Figs. 1 and 2).  When compared with Runx2 +/- cells or wild type MEFs (not shown), Runx2 -/- 
cells grown in osteogenic medium had markedly reduced mineralization (Suppl. Fig. 1A) and 
expressed very low levels of Bglap2 and Ibsp (Suppl. Fig. 1B-D). In contrast, adipocyte 
differentiation was dramatically increased in these cells as assessed by induction of Pparg, 
! ""!
increased lipid droplet accumulation and up-regulation of the adipocyte markers Cebpa and 
Fabp4 (Suppl. Fig. 1E-H). A parallel experiment was conducted using MEFs from Pparg +/- and 
Pparg -/- embryos (Suppl. Fig. 2). In this case, lipid droplet accumulation (Suppl. Fig. 2E) and 
adipocyte marker mRNA expression were strongly suppressed in Pparg -/- cells, but expression 
of Runx2 and osteoblast differentiation were greatly increased (Suppl. Fig. 2A-D). Thus, in the 
absence of an osteogenic RUNX2 signal, PPAR! is up-regulated and adipocyte differentiation 
predominates, whereas RUNX2 induction and osteogenesis preferentially occurs in the Pparg -/- 
MEFs. These results are consistent with previous reports showing that adipocyte formation is 
increased in cells derived from Runx2 -/- mice while PPAR! deficiency increases osteoblast 
differentiation (Akune et al., 2004; Cho et al., 2011; Enomoto et al., 2004). 
 We next investigated the impact of the phosphorylation site mutations on activities of 
RUNX2 and PPAR!. After generation of stable MEF cell pools expressing equivalent levels of 
wild type or mutant RUNX2 (RUNX2-WT, RUNX2-SA, RUNX2-SE) or PPAR! (PPAR!-WT, 
PPAR!-SA, PPAR!-SE) (Fig. 4A,D, Fig. 5A,G), cells were grown in osteogenic or adipogenic 
media for analysis of differentiation. Consistent with previous results (Bae et al., 2007; Ge et al., 
2009), introduction of wild type RUNX2 into Runx2 -/- MEFs increased mineralization and 
osteoblast marker mRNAs (Fig 4B,E,F). Notably, RUNX2 also strongly suppressed lipid droplet 
accumulation, as well as expression of Pparg and other adipocyte marker mRNAs (Fig. 3C, G-
H). In comparison to wild type RUNX2, expression of RUNX2 SA had notably weaker effects 
on stimulating mineralization and induction of Ibsp and Bglap2. This mutant was also 
considerably less active than wild type protein in suppressing adipocyte differentiation (Fig. 3C, 
G-H). On the other hand, RUNX2 SE was a more potent inducer of osteoblast differentiation 
than wild type protein and a stronger inhibitor of PPAR! and adipocyte differentiation.  
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 Diametrically opposite results were obtained with PPAR! rescue; introduction of wild type 
PPAR! into Pparg -/- MEFs restored lipid droplet accumulation and adipocyte marker mRNAs 
(Fig. 5C, G-J) while reducing levels of Runx2, osteoblast markers and mineralization (Fig. 5B, 
D-F). Significantly, MEFs expressing the PPAR! S112A mutant, which cannot be 
phosphorylated and inhibited by MAP kinase, exhibited even higher adipogenic activity than 
wild type PPAR! cells, but did not mineralize in osteogenic medium and had very low osteoblast 
marker expression. Lastly, PPAR! S112E MEFs had only slightly more adipogenic activity than 
EV MEFs (Fig. 5C, H-I) and expressed somewhat higher levels of osteoblast markers than wild 
type PPAR! MEFs (Fig. 5D-F), consistent with the reduced transcriptional activity of this 
phosphomimetic PPAR! mutant. 
 
Transcriptional antagonism between RUNX2 and PPAR!  is affected by phosphorylation 
state. The studies described in Figures 4 and 5 showed that PPAR! is up-regulated in Runx2 -/- 
MEFs and that re-introduction of RUNX2 can reverse this process. Furthermore, the 
phosphomimetic RUNX2-SE mutant is even more effective than wild type or phosphorylation-
deficient RUNX2-SA in suppressing PPAR! and inducing osteoblast differentiation. Similarly, 
RUNX2 is up-regulated in Pparg -/- MEFs and this up-regulation is reversed by rescue with 
PPAR!. Consistent with the concept that phosphorylation reduces PPAR! activity, PPAR!-SE 
was less active than wild type or PPAR!-SA in suppressing RUNX2 and stimulating adipocyte 
differentiation.  
 To begin to explore the basis for the mutually antagonistic actions of RUNX2 and PPAR!, 
we examined whether these two factors can interfere with each other at the transcriptional level 
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and whether such inhibition depends on their phosphorylation state (Fig. 6). Studies shown in 
Fig. 6A-B examined the ability of wild type PPAR!, PPAR!-SA or PPAR!-SE to inhibit 
RUNX2-dependent transcription, as measured in COS7 cells transfected with a 6OSE2-Luc 
RUNX2 reporter gene, RUNX2-SE and RXR expression vectors.  The phosphomimetic 
RUNX2-SE mutant was used because it does not require phosphorylation for full activity (see 
Fig. 2A,B), thereby simplifying competition experiments with PPAR!. RUNX2 transcriptional 
activity was dose-dependently inhibited by PPAR!; the phosphorylation-resistant PPAR!-SA 
mutant had the strongest inhibitory activity, followed by wild type PPAR! and then PPAR!-SE. 
As shown in Fig. 6B, RUNX2-SE protein levels remained constant in all samples and titration 
with wild type and mutant PPAR! expression vectors gave similar dose-dependent increases in 
protein. These results cannot, therefore, be explained by differences in expression or stability of 
PPAR! or RUNX2.  
 The ability of different phospho-mutants of RUNX2 to inhibit PPAR! transcriptional 
activity was also examined (Fig. 6C,D). In this experiment, all cells were transfected with an 
ARE-luc PPAR! reporter gene, RXR and PPAR!-SA, which is resistant to inhibition by 
phosphorylation (see Fig. 2C,D). We found that RUNX2 dose-dependently inhibited PPAR! 
transcriptional activity, with the phosphomimetic RUNX2-SE mutant being the strongest 
inhibitor, followed by wild type RUNX2 and RUNX2-SA (Fig. 6C). PPAR! protein levels 
remained constant in all samples and titration with wild type or mutant RUNX2 expression 
vectors gave similar dose-dependent increases in protein (Fig. 6D). 
 These studies show that RUNX2 and PPAR! are mutually antagonistic at the transcriptional 
level. Furthermore, inhibitory activity is affected by phosphorylated state, with the 
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phosphorylation-resistant PPAR! S112A mutant being the strongest inhibitor of RUNX2-
dependent transcription and the S301E,S319E phosphomimetic RUNX2 mutant being the most 
potent inhibitor of PPAR!.  
 Jeon and coworkers previously reported that PPAR! could inhibit RUNX2-dependent 
induction of the osteocalcin gene (Jeon et al., 2003). They proposed that this inhibition might be 
explained by formation of a complex containing these two transcription factors, leading to 
decreased binding of RUNX2 to specific enhancer sequences in the osteocalcin promoter. While 
we were able to detect RUNX2-PPAR! complexes using co-immunoprecipitation assays, no 
differences in complex formation were observed between wild type proteins or phosphorylation 
site mutants (Supplementary Fig. S3). Thus, it is unlikely that differences in RUNX2-PPAR! 
complex formation can explain the different inhibitory activities of wild type versus 
phosphorylation-site-mutant proteins. 
 
Discussion 
 Here we describe the importance of MAPK signaling in the control of mesenchymal 
progenitor differentiation to osteoblasts versus adipocytes and establish the important role of 
RUNX2 and PPAR! phosphorylation in this process. These studies provide a plausible 
mechanism to explain how external signals including mechanical loading can alter 
osteoblast/adipocyte ratio and bone formation and suggest a possible target for therapeutic 
modification of marrow fat and bone mass. Previous work showed that PPAR! together with its 
TZD agonists potently decrease bone mass (Lecka-Czernik, 2010). However, this is the first 
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study to describe how phosphorylation can regulate the ability of PPAR! to disrupt osteoblast 
differentiation and, conversely, the ability of RUNX2 to block adipogenesis.  
 The mechanistic basis for the increased RUNX2-dependent transcription following MAPK 
phosphorylation and activation has been examined in several contexts, including in response to 
collagen matrix accumulation/integrin activation during osteoblast differentiation (Ge et al., 
2009; Li et al., 2010), FGF2 (Park et al., 2010; Xiao et al., 2002b) and mechanical loading (Li et 
al., 2012). Subsequent to MAPK activation, P-ERK translocates from perinuclear to nuclear sites 
where it binds and phosphorylates RUNX2 previously bound to promoter regions of target genes 
(Li et al., 2010; Li et al., 2012). These events are necessary for subsequent changes in histone 
acetylation and transcription. Although P-ERK phosphorylates RUNX2 on at least 4 serine 
residues, S301 and S319 phosphorylation sites are the most important for transcriptional 
activation (Ge et al., 2009).  
 The negative regulation of PPAR! activity and adipogenic functions by MAP kinase-
dependent phosphorylation at S112 has also been extensively studied (for review, see (van 
Beekum et al., 2009). Phosphorylation inhibits both ligand-dependent and ligand-independent 
activity. Transcriptional repression is achieved through multiple mechanisms including inhibition 
of ligand binding and phosphorylation-dependent increased K107 sumoylation followed by 
recruitment of a repressor complex (Shao et al., 1998; Yamashita et al., 2004). Mutation of S112 
to A renders PPAR! resistant to MAPK inhibition, thereby increasing transcriptional activity and 
ability to induce adipogenesis relative to wild type PPAR! (Adams et al., 1997; Hu et al., 1996). 
In contrast to RUNX2, it is not known if PPAR! interacts with P-ERK while on the chromatin of 
target genes, or if binding occurs before translocation of PPAR! to the nucleus.  
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 Of the many signals that regulate both bone formation and marrow adipogenesis, skeletal 
loading is of particular interest. Exposure of mice to low magnitude mechanical strain can 
preferentially increase differentiation of marrow stromal cells to osteoblasts and decrease 
adipocyte formation (Luu et al., 2009). In vitro exposure of MSCs or adipocytes to biaxial 
mechanical strain or fluid shear also inhibits adipocyte differentiation and stimulates osteoblast 
formation (David et al., 2007; Sen et al., 2008; Tanabe et al., 2004). Conversely, skeletal 
unloading stimulates marrow adipogenesis and decreases bone formation through a pathway 
involving PPAR! (Marie and Kaabeche, 2006). These changes also occur in paraplegic patients 
where increased marrow adiposity is associated with disuse osteopenia (Minaire et al., 1984). 
Although mechanical loading stimulates a broad range of signals (integrin-focal adhesion kinase, 
Wnt/#-catenin, COX2 activation/PGE2 production and Rho/ROCK signaling), in all cases these 
pathways directly or indirectly interact with MAPK. For example, cell stretching or exposure to 
fluid flow shear stress activates integrin signaling followed by activation of focal adhesion 
kinase and MAPK (Young et al., 2009). Other loading-induced signals such as activation of 
Rho/ROCK and Wnt signaling indirectly activate or are themselves activated by MAPK 
(Cervenka et al., 2011; Lessey et al., 2012; Robling, 2013). Thus, activation of the MAPK 
pathway is a common loading-induced signal in bone that can stimulate differentiation of 
marrow cells to osteoblasts and away from adipocytes via phospho-regulation of RUNX2 and 
PPAR!. 
 The basis for the observed ability of RUNX2 to suppress adipocyte gene expression and, 
conversely, for PPAR# to inhibit osteoblast genes, as well as the role of transcription factor 
phosphorylation in this process, is still not completely understood. One possibility is that 
RUNX2 and PPAR! can suppress each other at the transcriptional level. Rescue experiments 
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with    Runx2 -/- and Pparg -/- cells showed a reciprocal relationship between levels of these two 
factors, whereby Runx2 -/- MEFs exhibited strong up-regulation of Pparg that was repressed by 
stable reintroduction of RUNX2, while Pparg -/- cells expressed high levels of Runx2 message 
that was suppressed by PPAR! (Suppl. Figs 2,3; Figs 3, 4). However, further studies will be 
required to determine if Runx2 or PPAR! can directly suppress the promoters of Pparg or 
Runx2, respectively, or if inhibition is indirect.  
 The experiment shown in Fig. 6 argues that there is additional antagonism between these 
two factors at the target gene level via mutual inhibition. Here, studies with a simple Runx2 
reporter gene revealed that PPAR! can inhibit Runx2 transcriptional activity, while the converse 
studies demonstrate that RUNX2 inhibits PPAR#-dependent transcription from a PPAR! 
reporter. In both cases, mutation of transcription factor phosphorylation sites affected repressive 
activity. The phosphomimetic RUNX2 SE mutant had greater inhibitory activity than the 
phosphorylation resistant RUNX2-SA mutant. Conversely, the phosphorylation resistant PPAR!-
SA mutant was a more potent inhibitor of RUNX2 transcription when compared with the 
phosphomimetic mutant, PPAR!-SE. It was previously reported (Jeon et al., 2003) and 
confirmed in the present study (Suppl. Fig. 3) that PPAR# and RUNX2 can form a stable 
complex. Binding of PPAR! to RUNX2 was reported to prevent its association with an OSE2-
containing double-stranded oligonucleotide on electrophoresis mobility shift assays, suggesting 
that sequestration of RUNX2 can block its transcriptional activity (Jeon et al., 2003), However, 
we were unable to obtain evidence that phosphorylation state of either PPAR# or RUNX2 affects 
complex formation. This suggests that phosphorylation state affects the interaction of RUNX2 
and PPAR! with other factors that are necessary for transcriptional activation/repression.  
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Figure Legends 
Figure 1. Regulation of MAP kinase, Runx2 and PPAR!  phosphorylation during osteoblast 
and adipocyte differentiation. ST2 mesenchymal cells were cultured in growth medium (GM) , 
! #%!
adipogenic medium (adipo) or osteogenic medium (osteo). Cells were stained with Oil Red O 
after 1 week or Alizarin Red  after  3 weeks (A) or extracted for total protein after 1 week (B). 
RNA was isolated at the times indicated (C-I). (B) Immunoblot analysis of MAP kinase 
activation and Runx2/PPAR!  phosphorylation. Samples were probed with antibodies to 
pERK1/2, total ERK, PPAR!-S112-P, total PPAR!, Runx2-S319-P and total Runx2 as indicated. 
(C-E) Osteoblast marker mRNAs. Runx2 (C), Bglap2 (D), Ibsp (E). (F-I) Adipocyte marker 
mRNAs. Pparg (F), Cebpb (G), Adipoq (H) and Fabp4 (I).  
 
Figure 2. MAP kinase-dependent phosphorylation stimulates RUNX2 transcriptional 
activity while suppressing PPAR! . (A,B) RUNX2. COS7 cells were transfected with 6OSE2-
luc reporter plasmid and expression vectors for wild type (WT) or phosphorylation mutant 
RUNX2 (S301A,S319A, SA; S301E,S319E, SE) and constitutively-active (SP) or dominant-
negative MEK1 (DN). (A) normalized luciferase activity; (B) immunoblot of RUNX2-S319-P 
and total RUNX2. (C,D) PPAR! . Parallel transfections were conducted with ARE-luc reporter 
plasmid and expression vectors encoding wild type (WT) or phosphorylation site mutant PPAR! 
(S112A, SA; S112E, SE) and constitutively-active (SP) or dominant-negative MEK 1 (DN). 
Cells were treated with vehicle (-) or troglitazone (TZD) as indicated. (C) normalized luciferase 
activity; (D) immunoblot of PPAR!-S112-P and total PPAR!.  * Statistical comparisons are 
indicated by bars;  P <  0.001, n = 3. 
 
Figure 3. Opposing actions of MAP kinase on osteoblast and adipocyte differentiation. ST2 
cells were transduced with control adenovirus expression vector (LacZ) or vector encoding 
! #&!
constitutively-active (Meksp) or dominant-negative (Mekdn) MEK1 and grown in osteogenic 
(A-E) or adipogenic medium (F-K). (A-E) Osteoblast differentiation. (A) Alizarin Red 
staining, (B) Immunoblot detection of pERK, total ERK, RUNX2-S319-P and total 
RUNX2. (C-E) Osteoblast marker mRNAs; Runx2 (C), Bglap2 (D), Ibsp (E). (F-K) 
Adipocyte differentiation. (F) Oil Red O staining, (G) Immunoblot detection of pERK, total 
ERK, PPAR!-S112-P and total PPAR! . (H-K) Adipocyte marker mRNAs. Pparg (H), 
Cebpa (I), Adipoq (J) and Fabp4 (K). * Statistical comparisons are indicated by bars;  P <  
0.001, n = 3. 
 
Figure 4. Regulation of osteoblast and adipocyte differentiation by wild type and 
phosphorylation site mutant RUNX2. MEFs from Runx2-/- mice were transduced with empty 
vector (EV) or retrovirus expressing wild type (WT), S301A,S319A (SA) or S301E,S319E 
RUNX2 (SE). After selection, stable cell pools were grown in osteogenic (B, D-F) or adipogenic 
medium (C, G-J). (A) Western blot of total RUNX2 protein. (B) Alizarin Red staining. (C) 
Oil Red O staining. (D-F) osteoblast marker mRNAs. (G-J) adipocyte marker mRNAs. 
Statistical comparisons; a, Runx2-WT vs. empty vector P < 0.001; b, Runx2-SA vs. Runx2-WT 
P < 0.001; c, Runx2-SE vs. Runx2-WT. P < 0.001, n = 3. 
 
Figure 5. Regulation of osteoblast and adipocyte differentiation by wild type and 
phosphorylation site mutant PPAR! . MEFs from Pparg-/- cells were transduced with empty 
vector (EV) or retrovirus expressing wild type (WT), S112A (SA) or S112E mutant PPAR! (SE). 
Stable cell pools were grown in osteogenic (B, D-F) or adipogenic medium (C, G-J). (A) 
! #'!
Western blot of total PPAR!  protein. (B) Alizarin Red staining. (C) Oil Red O staining. (D-
F) osteoblast marker mRNAs. (G-J) adipocyte marker mRNAs. Statistical comparisons; a, 
PPAR!-WT vs. empty vector P < 0.001; b, PPAR!-SA vs. Runx2-WT P < 0.001; c, PPAR!-SE 
vs. PPAR!-WT. P < 0.001, n = 3. 
 
Figure 6. Antagonism between RUNX2 and PPAR!  is affected by phosphorylation state. 
(A,B) PPAR!  inhibition of RUNX2 transcriptional activity. COS7 cells were transfected with 
a RUNX2 reporter plasmid (p6OSE2-luc), RUNX2-SE vector and the indicate amounts of wild 
type, SA or SE PPAR! vectors. A, luciferase activity; B, PPAR! and RUNX2 protein levels. 
(C,D) RUNX2 inhibition of PPAR!  transcriptional activity. Cells were transfected with a 
PPAR! reporter plasmid (pARE-luc), PPAR!-SA and RXR vectors and the indicated amounts of 
wild type, SA or SE RUNX2. (C) luciferase activity, (D) RUNX2 and PPAR! protein. Statistical 
comparisons; a, PPAR!-SA vs. PPAR!-WT (Panel A) or Runx2-SA vs. Runx2-WT (Panel B); b, 
PPAR!-SE vs. PPAR!-WT (Panel A) or Runx2-SE vs. Runx2-WT (Panel B). P < 0.001, n = 3. 






Supplementary Figures. Ge et al. 
 
Supplementary Figure 1. Decreased osteoblastogenesis  and increased adipogenesis in MEF 
cells from Runx2-null mice. MEF cells were isolated from Runx2 +/- and -/- mice as described 
in Methods and grown in osteogenic or adipogenic medium for the times indicated. Cells were 
stained for mineral (A) or lipid droplet accumulation (E). RNA was isolated at the times 
indicated for measurement of osteoblast (B-D) and adipocyte marker expression (F-H) using Q-
RT/PCR. 
 
 
 
Supplementary Figure 2. Increased osteoblastogenesis and decreased adipogenesis in MEF 
cells from PPAR!-null mice. MEF cells were isolated from PPAR! +/- and PPAR! -/- mice and 
analyzed for osteoblast and adipocyte formation as in Suppl Figure 2. Cells were stained for 
mineral (A) or lipid droplet accumulation (E). RNA was isolated at the times indicated for 
measurement of osteoblast (B-D) and adipocyte marker expression (F-H) using Q-RT/PCR. 
 
 
 
  
Supplementary Figure 3. Complex formation between RUNX2 and PPAR!  is not affected 
by phosphorylation site mutation. COS7 were transfected with wild type or mutant RUNX2 
and PPAR! as indicated. Cell extracts were either immunoprecipitated with anti-PPAR! antibody 
and probed with anti-RUNX2 antibody or were immunoprecipitated with anti-RUNX2 antibody 
and probed with anti-PPAR! as indicated. The 1st and 5th lanes show non-specific 
immunoprecipitation with isotype-matched IgG. 
 
